Kaposi Sarcoma Updates

Dermatol Clin. 2019 Oct;37(4):505-517. doi: 10.1016/j.det.2019.05.008. Epub 2019 Jul 10.

Abstract

Kaposi sarcoma (KS) is an angioproliferative mesenchymal neoplasm caused by Kaposi sarcoma-related herpesvirus. This review outlines our current understanding of the epidemiology, pathogenesis, clinical presentation, and staging for this disease. Recent research has informed a more comprehensive understanding of the epidemiology of KS in the post-antiretroviral therapy era, and highlights the continued need to better characterize the African endemic subtype. Advances in clinical oncology, including checkpoint inhibitors and new skin-directed therapies, have translated into exciting new developments for the future of KS treatment options.

Keywords: AIDS; HHV8; HIV; Immunosuppression; Kaposi sarcoma; Sarcoma.

Publication types

  • Review

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Acquired Immunodeficiency Syndrome / epidemiology
  • Administration, Cutaneous
  • Anti-HIV Agents / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents, Immunological / therapeutic use
  • Antiviral Agents / therapeutic use
  • Brachytherapy
  • Cryosurgery
  • Herpesviridae Infections / drug therapy*
  • Herpesviridae Infections / epidemiology
  • Herpesviridae Infections / pathology
  • Herpesvirus 8, Human
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Injections, Intralesional
  • Laser Therapy
  • Radiotherapy
  • Sarcoma, Kaposi / epidemiology
  • Sarcoma, Kaposi / pathology
  • Sarcoma, Kaposi / therapy*
  • Sarcoma, Kaposi / virology
  • Skin Neoplasms / epidemiology
  • Skin Neoplasms / pathology
  • Skin Neoplasms / therapy*
  • Skin Neoplasms / virology

Substances

  • Anti-HIV Agents
  • Antineoplastic Agents
  • Antineoplastic Agents, Immunological
  • Antiviral Agents
  • Immunosuppressive Agents